What Is Trulicity (Dulaglutide)?
Trulicity is a long-acting GLP-1 receptor agonist indicated for adults with type 2 diabetes. It is administered as a once-weekly subcutaneous injection and works by enhancing your body's glucose-dependent insulin response, suppressing inappropriate glucagon secretion, and slowing gastric emptying. Many patients also experience appetite reduction and clinically meaningful weight loss as secondary benefits.
How Trulicity Works
Glucose-Dependent InsulinEnhances insulin secretion only when blood sugar is elevated, which keeps the risk of low blood sugar lower than with insulin or sulfonylureas.
Slower Gastric EmptyingSlows how quickly food leaves the stomach, which reduces post-meal blood sugar spikes and helps some patients eat less.
Trulicity and other GLP-1 medications like Ozempic, Wegovy, and Mounjaro work within the same incretin pathway but use different molecules and have different approved indications. Your Vitercure clinician will assess which is most appropriate.
Trulicity for Type 2 Diabetes Control
Trulicity is primarily a type 2 diabetes medication. In the AWARD trial program, dulaglutide 1.5mg produced A1C reductions of up to 1.5% when added to diet, exercise, and in some studies, baseline metformin therapy.
- A1C reduction: Up to 1.5% at the 1.5mg dose in the AWARD trials, depending on baseline A1C and concomitant therapy.
- Hypoglycemia risk: Lower than insulin or sulfonylureas because the effect is glucose-dependent. Risk increases when combined with those medications.
- Cardiovascular: The REWIND trial showed a 12% reduction in major adverse cardiovascular events (heart attack, stroke, CV death) in type 2 diabetes patients.
How to Use Trulicity
- Form: Single-use, pre-filled pen for subcutaneous injection.
- Frequency: Once weekly, same day each week.
- Sites: Abdomen, thigh, or upper arm. Rotate sites.
- With food: Can be given with or without food.
- Storage: Refrigerate at 36 to 46 degrees F. Can be at room temperature for up to 14 days.
| Phase | Weekly Dose | Purpose |
|---|
| Initiation | 0.75mg once weekly | Assess tolerability and begin GLP-1 therapy. |
| Maintenance | 1.5mg once weekly | Sustained A1C reduction if tolerated and indicated. |
Your actual dose and duration will be determined by your Vitercure clinician based on your history, labs, and concurrent medications.
Important Safety Information for Trulicity
This is not a complete list. Always review the full Prescribing Information and speak with a licensed clinician.
Do Not Use If:
- Personal or family history of medullary thyroid carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Serious hypersensitivity to dulaglutide or any component.
- Pregnant or planning pregnancy, unless advised by your clinician.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, indigestion, and fatigue. Usually worst during initiation and often improve over time. Severe abdominal pain, signs of pancreatitis, difficulty breathing, or allergic reactions require urgent medical evaluation.
Frequently Asked Questions About Trulicity
Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist used to improve blood sugar control in adults with type 2 diabetes. Many patients also experience weight reduction as a secondary benefit when combined with diet and exercise.
Trulicity is not classified as a dedicated weight loss medication, but many patients lose weight as a secondary benefit. This effect is related to appetite regulation, slower gastric emptying, and improved insulin and glucose dynamics. For dedicated weight loss, GLP-1 medications like Wegovy or Zepbound are typically more effective.
Once weekly, on the same day each week, with or without food. Injection sites include the abdomen, thigh, or upper arm. Rotate sites each week. Never change your dose or schedule without guidance from your clinician.
Trulicity is often used alongside metformin, SGLT2 inhibitors, or basal insulin. However, combinations must be individualized. Your prescriber will review your medications, kidney function, and hypoglycemia risk before recommending a regimen.
Both are once-weekly GLP-1 receptor agonists for type 2 diabetes, but they contain different active ingredients (dulaglutide vs semaglutide). Ozempic (semaglutide) generally produces somewhat greater A1C and weight reductions in head-to-head trials. Your clinician will consider your full profile when recommending one over the other.
Yes. Through Vitercure, a licensed clinician reviews your medical history through our HIPAA-compliant telehealth platform and can prescribe Trulicity if appropriate. Prescriptions are fulfilled by licensed US pharmacy partners with temperature-controlled shipping.
Nausea, vomiting, diarrhea, decreased appetite, indigestion, and fatigue are frequently reported, especially during initiation. These often improve over time. Severe abdominal pain, signs of pancreatitis, or allergic reactions require urgent medical evaluation.
